1. An 81-year-old woman with Parkinson's disease dementia, maintained at baseline on rivastigmine transdermal patch 9.5 mg/24 hr and carbidopa/levodopa, is admitted for a hip replacement. On admission, the surgical team places her medications under review and withholds the rivastigmine patch for three days pending a pharmacist's medication reconciliation. By postoperative day three she is confused, agitated, unable to recognize her daughter, and is pulling at her IV lines. Her cognition at baseline was described as mild-to-moderate impairment with preserved recognition of family. The surgical team attributes the delirium to anesthesia and requests a psychiatry consult for haloperidol. Which of the following represents the most pharmacologically appropriate immediate intervention?
A) Administer haloperidol 0.5 mg IV as requested — postoperative delirium in elderly patients is a well-recognized complication of general anesthesia and requires antipsychotic sedation; the rivastigmine can be restarted once the delirium resolves
B) Start a low-dose benzodiazepine infusion to sedate the patient safely while awaiting psychiatry review; rivastigmine's slow onset of action means restarting it will not contribute meaningfully to acute delirium management
C) Immediately restart the rivastigmine patch and decline the haloperidol order; the acute cognitive deterioration is consistent with cholinergic deficiency from abrupt cholinesterase inhibitor withdrawal in a patient with severe baseline cholinergic deficit, and haloperidol — a high-potency D2 blocker — is contraindicated in Parkinson's disease and will cause severe motor worsening
D) Request a brain CT scan before any pharmacological intervention to exclude a postoperative intracranial event as the cause of the acute cognitive change; pharmacological management should be deferred until structural pathology is ruled out
E) Switch from the rivastigmine patch to oral donepezil because donepezil has a faster onset of action in acute settings and will more rapidly restore cholinergic tone to resolve the delirium; restart rivastigmine after discharge
ANSWER: C
Rationale:
This vignette requires recognizing two simultaneous errors and correcting both. First, withholding rivastigmine in a patient with Parkinson's disease dementia is a serious omission: PDD is associated with a cholinergic deficit more severe than in Alzheimer's disease, and abrupt discontinuation of a cholinesterase inhibitor in this context removes the pharmacological support for the patient's already-compromised cholinergic neurotransmission. The resulting acute cognitive deterioration and agitation are consistent with cholinergic deficiency superimposed on the well-established vulnerability of PDD patients to any added physiological stress. The rivastigmine patch must be immediately reapplied. Second, haloperidol is a high-potency dopamine D2 receptor antagonist that is contraindicated in Parkinson's disease — it will cause severe and potentially irreversible worsening of motor function, converting a manageable delirium into an akinetic, dysphagic crisis. The appropriate antipsychotic if one were genuinely needed would be quetiapine at very low doses or pimavanserin, neither of which should be the immediate response before addressing the medication omission.
Option A: Option A is incorrect because haloperidol is contraindicated in PD regardless of the clinical urgency of the delirium — D2 blockade will cause severe motor deterioration — and attributing the delirium to anesthesia alone without addressing the three-day rivastigmine withdrawal omits the most correctable contributing cause.
Option B: Option B is incorrect because benzodiazepines will add sedation and respiratory depression risk in an elderly postoperative patient while doing nothing to address the pharmacological deficit driving the deterioration; sedation is not the appropriate response to cholinergic withdrawal.
Option D: Option D is incorrect because while structural pathology should eventually be excluded, deferring all pharmacological management pending imaging when a clear pharmacological cause — three days of rivastigmine withdrawal — is already identified delays a directly correctable intervention and allows further cognitive decline.
Option E: Option E is incorrect because donepezil does not have a meaningfully faster onset of action than rivastigmine in acute settings, and switching formulations introduces unnecessary complexity and delay when the appropriate intervention is simply restarting the patient's established agent.
2. A 73-year-old man with Parkinson's disease and neurogenic orthostatic hypotension is taking midodrine 5 mg three times daily (last dose at 5 PM) and fludrocortisone 0.2 mg once daily. At his clinic visit, his standing blood pressure after one minute is 86/54 mmHg with symptoms of lightheadedness, but his blood pressure measured supine at home at midnight by his wife has been consistently 186/108 mmHg on three separate nights. He has no history of heart failure. His neurologist wants to make a single pharmacological adjustment to reduce his nocturnal supine hypertension without sacrificing his daytime orthostatic blood pressure support. Which of the following is the most appropriate intervention?
A) Discontinue midodrine entirely and rely on fludrocortisone alone for orthostatic blood pressure support; midodrine's peripheral alpha-1 agonism is responsible for the supine hypertension because it causes indiscriminate vasoconstriction regardless of body position
B) Add an evening dose of a short-acting antihypertensive such as captopril 6.25 mg at bedtime to blunt the nocturnal hypertensive surge while preserving daytime orthostatic support from both agents
C) Increase the midodrine dose to 10 mg three times daily to achieve better daytime orthostatic control, which will allow the fludrocortisone to be tapered; the supine hypertension is caused by fludrocortisone's volume expansion rather than midodrine's vasoconstriction
D) Discontinue fludrocortisone and add droxidopa 100 mg three times daily; droxidopa generates norepinephrine only during upright posture because aromatic L-amino acid decarboxylase is gravity-dependent, making it mechanistically incapable of causing supine hypertension
E) Reduce the fludrocortisone dose from 0.2 mg to 0.1 mg daily; at 0.2 mg the mineralocorticoid-mediated plasma volume expansion is likely contributing to the supine hypertension, and a dose reduction is the most targeted single adjustment that addresses the mechanism without eliminating a component of orthostatic support
ANSWER: E
Rationale:
This vignette requires applying the mechanisms of both agents to explain the clinical picture and identify the most targeted adjustment. Fludrocortisone at 0.2 mg daily is at the upper end of the typical dosing range for neurogenic orthostatic hypotension; at this dose, the mineralocorticoid-mediated sodium and water retention produces plasma volume expansion that raises blood pressure in all positions, including supine. Reducing the dose to 0.1 mg directly addresses the mechanism of supine hypertension while preserving some volume-mediated orthostatic support. Midodrine's last dose was already appropriately timed at 5 PM — well before bedtime — which is the standard measure to limit midodrine-related supine hypertension. Since midodrine timing is already optimized, the fludrocortisone dose is the most appropriate target for adjustment.
Option A: Option A is incorrect because midodrine, taken with the last dose at 5 PM, will have substantially cleared by midnight given its active metabolite desglymidodrine's half-life of approximately two to three hours; blaming midodrine for the midnight hypertension when it was last taken at 5 PM is pharmacokinetically inconsistent, and discontinuing it entirely would eliminate an important component of daytime orthostatic support.
Option B: Option B is incorrect because adding an evening antihypertensive introduces a new drug that will blunt the same volume expansion during the day — when it is needed for orthostatic support — if its duration of action extends into daytime hours; a dose reduction of fludrocortisone is more mechanistically precise than adding a blood pressure-lowering agent on top.
Option C: Option C is incorrect because increasing midodrine will worsen rather than improve supine hypertension by adding more vasoconstriction during any period when plasma concentrations remain active; the clinical problem is not insufficient daytime control but nocturnal hypertension, and escalating a vasopressor is the wrong direction.
Option D: Option D is incorrect because droxidopa's conversion to norepinephrine by aromatic L-amino acid decarboxylase is not gravity-dependent; AADC is a ubiquitous enzyme present throughout the body regardless of posture, and droxidopa-derived norepinephrine causes supine hypertension by the same mechanism as any other vasopressor — the claim that it is incapable of causing supine hypertension is pharmacologically false.
3. A 69-year-old man with Parkinson's disease for eight years presents with a six-week history of formed visual hallucinations — he sees children playing in his living room that he knows are not there. His cognition is intact and he recognizes the hallucinations as unreal. His current medications are carbidopa/levodopa 25/100 mg four times daily, pramipexole 1 mg three times daily, rasagiline 1 mg once daily, and amantadine 100 mg twice daily, which was added eight months ago for levodopa-induced dyskinesia. He asks whether he needs an antipsychotic. Before any antipsychotic is initiated, what is the most pharmacologically appropriate next step?
A) Taper and discontinue amantadine, as it has significant psychotogenic potential through its glutamate NMDA antagonist and indirect dopaminergic mechanisms, and is a higher-priority target for reduction than the other agents given that it was added relatively recently and its contribution to dyskinesia control can be reassessed after the psychosis is managed
B) Start pimavanserin 34 mg once daily immediately, as the hallucinations are already present for six weeks and represent established Parkinson's disease psychosis requiring FDA-approved pharmacological treatment without delay
C) Reduce the carbidopa/levodopa dose by 50% as the first step, since levodopa is the primary psychotogenic agent in any PD regimen and its dose reduction will produce the most rapid and reliable reduction in hallucination severity
D) Start low-dose quetiapine 12.5 mg at bedtime in addition to his current regimen, since all his current medications are at doses established for motor control and none should be reduced without risking motor decompensation
E) Refer the patient for deep brain stimulation evaluation, as persistent visual hallucinations in PD indicate refractory motor fluctuations that are driving the psychosis through excessive dopaminergic stimulation during on periods; surgical management addresses both motor fluctuations and associated psychosis simultaneously
ANSWER: A
Rationale:
This vignette requires applying the PD psychosis medication-reduction sequence to a patient whose regimen includes amantadine — a drug with dual psychotogenic mechanisms. Amantadine causes hallucinations through two pathways: its NMDA glutamate receptor antagonism disrupts normal cortical network activity in ways that promote psychosis, and its indirect dopaminergic properties (promoting dopamine release and blocking reuptake) add to the overall dopaminergic burden. Critically, amantadine was added only eight months ago and its removal is the most reversible recent pharmacological change. The established sequence for PD psychosis management requires removing anticholinergic agents and amantadine first — before dopamine agonists, MAO-B inhibitors, COMT inhibitors, or levodopa — because their motor contribution is modest relative to their psychotogenic and cognitive risk. After amantadine is tapered, the hallucinations may resolve without any antipsychotic. If they persist, the sequence continues with dopamine agonist reduction.
Option B: Option B is incorrect because pimavanserin is not the first step — the medication-reduction sequence must precede antipsychotic initiation; starting pimavanserin before removing the identifiable psychotogenic contributor bypasses the most correctable cause.
Option C: Option C is incorrect because levodopa is the last agent to be reduced in the PD psychosis sequence precisely because it provides the most critical motor benefit; reducing it by 50% as a first step risks severe motor deterioration before less dangerous interventions have been tried.
Option D: Option D is incorrect because initiating quetiapine without first removing the identified psychotogenic agent adds a drug with motor risk and limited efficacy evidence for PDP before attempting the pharmacologically correct first step of medication reduction.
Option E: Option E is incorrect because deep brain stimulation addresses motor fluctuations but does not reliably resolve PD psychosis, and this patient's hallucinations are occurring in the context of a recently added psychotogenic agent — surgery is not the appropriate first response to a pharmacologically addressable problem.
4. A 76-year-old woman with Parkinson's disease psychosis has been on pimavanserin 34 mg once daily for four months with good control of her hallucinations and no motor worsening. She is also taking azithromycin for a respiratory infection prescribed by her primary care physician, who was unaware of her pimavanserin. A routine electrocardiogram obtained for an unrelated pre-procedure evaluation shows a QTc interval of 498 milliseconds. Her QTc before starting pimavanserin was 432 ms. She is now on day five of a seven-day azithromycin course. What is the most appropriate immediate pharmacological management?
A) Continue both pimavanserin and azithromycin unchanged; a QTc of 498 ms is within the normal range for elderly women, who physiologically have longer QTc intervals than men, and no action is required until the QTc exceeds 550 ms
B) Discontinue pimavanserin immediately given the QTc of 498 ms in the context of concurrent azithromycin — both drugs prolong the QTc through hERG channel blockade, and their combination has produced a 66 ms increase from baseline; a QTc above 500 ms is a recognized threshold for heightened torsades de pointes risk, and the azithromycin course should be completed while pimavanserin is withheld, with reassessment of the QTc and discussion of alternative antipsychotic options after the antibiotic course ends
C) Continue pimavanserin but stop azithromycin immediately and substitute a non-QTc-prolonging antibiotic; azithromycin is the sole cause of the QTc prolongation and pimavanserin can be safely continued once the macrolide is removed from the regimen
D) Reduce the pimavanserin dose to 17 mg (half the standard dose) to reduce its contribution to QTc prolongation while maintaining partial antipsychotic effect; azithromycin can be continued at the current dose since its QTc effect is negligible at standard antibiotic doses
E) Add magnesium sulfate supplementation to shorten the QTc interval while continuing both pimavanserin and azithromycin; magnesium is the standard pharmacological treatment for drug-induced QTc prolongation in the outpatient setting and will prevent torsades de pointes without requiring discontinuation of either agent
ANSWER: B
Rationale:
This vignette requires integrating pimavanserin's cardiac safety profile with the clinical significance of the measured QTc and the additive effect of concurrent azithromycin. A QTc of 498 ms represents a 66 ms increase from the patient's pre-pimavanserin baseline of 432 ms — a clinically significant rise driven by the additive hERG potassium channel blockade of both agents. A QTc above 500 ms is widely recognized as a threshold associated with substantially increased risk of torsades de pointes; approaching this threshold in the context of two concurrent QTc-prolonging drugs warrants immediate action. Since azithromycin is near the end of its prescribed course and is being given for an active infection, completing it is appropriate. Pimavanserin, as the longer-term agent without an acute infectious indication, should be withheld until the azithromycin is complete and the QTc can be remeasured. After recovery, alternative antipsychotic options with lower QTc risk — or rechallenge with pimavanserin if the QTc normalizes — can be considered.
Option A: Option A is incorrect because a QTc of 498 ms in a patient on two QTc-prolonging drugs is not within a range that requires no action; the 550 ms threshold cited is sometimes used for absolute discontinuation but does not mean that 498 ms in this context is safe — the trajectory and the combination are both concerning.
Option C: Option C is incorrect because pimavanserin itself contributes to QTc prolongation independent of azithromycin; the QTc was already at 498 ms on the combination, and continuing pimavanserin after stopping azithromycin does not eliminate the risk — the pre-pimavanserin baseline must be reassessed.
Option D: Option D is incorrect because a half-dose of pimavanserin is not a pharmacologically established or approved dose; the drug is formulated and dosed at 34 mg, and dose-splitting is not a validated risk-reduction strategy for QTc management.
Option E: Option E is incorrect because magnesium supplementation is used acutely in the inpatient management of torsades de pointes or severe QTc prolongation — it is not the standard outpatient management for drug-induced QTc prolongation near 500 ms; the correct intervention is removal of the offending drug.
5. A 77-year-old man with Parkinson's disease and mild cognitive impairment was started on clonazepam 0.5 mg at bedtime three weeks ago for polysomnography-confirmed REM sleep behavior disorder (RBD) after his wife was struck during a dream enactment episode. The RBD enactment behavior has improved, but his wife now reports that he is excessively sleepy during the day, has fallen twice in the past two weeks, and seems more confused than before starting the medication. His neurologist examines him and attributes the new symptoms to clonazepam's CNS depressant effects. What is the most appropriate pharmacological change?
A) Reduce the clonazepam dose to 0.25 mg at bedtime; the adverse effects are dose-dependent and a 50% dose reduction will maintain therapeutic benefit for RBD while eliminating the daytime sedation and cognitive impairment
B) Add modafinil 100 mg each morning to counteract the daytime sedation from clonazepam while continuing clonazepam at its current dose for RBD control; this combination is standard practice for managing clonazepam-related EDS in elderly PD patients
C) Discontinue clonazepam and start zolpidem 5 mg at bedtime; zolpidem selectively promotes sleep through alpha-1 GABA-A receptor subunit binding and does not affect the brainstem circuits responsible for RBD, providing sedation without worsening the underlying sleep disorder
D) Discontinue clonazepam and substitute melatonin 6 mg at bedtime; melatonin reduces RBD enactment behavior without the CNS depression, sedation, and fall risk that make clonazepam poorly tolerated in this patient with cognitive impairment and already-compromised gait stability
E) Continue clonazepam at the current dose and add rivastigmine to counteract the anticholinergic cognitive effects; clonazepam causes cognitive impairment through muscarinic receptor blockade, and cholinesterase inhibition directly reverses this mechanism
ANSWER: D
Rationale:
This vignette illustrates the principle established in the module that melatonin is the preferred pharmacological treatment for RBD in patients with cognitive impairment or high fall risk — precisely the patient described here. Clonazepam is the most efficacious pharmacological treatment for RBD in the general population, but its benzodiazepine-class CNS depressant effects — excessive sedation, impaired balance and coordination, and worsening of cognitive function — are substantially amplified in elderly patients with pre-existing cognitive impairment and PD-related gait instability. The two falls in three weeks are a direct safety signal that the risk-benefit balance has shifted. Melatonin 6 mg at bedtime provides clinically meaningful reduction in RBD enactment behavior through a mechanism that does not involve CNS depression, carries no fall risk, and does not worsen cognition — making it the appropriate substitution in this specific patient.
Option A: Option A is incorrect because dose reduction to 0.25 mg may reduce but will not eliminate the adverse effects in a patient with established cognitive impairment and recent falls; given that a safer alternative exists (melatonin), persisting with the problematic agent at a lower dose is not the optimal approach.
Option B: Option B is incorrect because adding modafinil to address clonazepam-induced sedation treats an adverse effect symptomatically rather than removing its cause; this approach adds another drug and its own adverse effect profile rather than substituting the safer agent.
Option C: Option C is incorrect because zolpidem is not an established or appropriate treatment for RBD — it promotes sleep through GABA-A receptor modulation but does not address the loss of REM atonia that drives enactment behavior, and zolpidem carries its own risks of complex sleep behaviors, falls, and cognitive impairment in elderly patients.
Option E: Option E is incorrect because clonazepam's cognitive and sedating effects are mediated through GABA-A receptor potentiation, not muscarinic receptor blockade; it is not an anticholinergic drug, and rivastigmine would not reverse benzodiazepine-mediated CNS depression through cholinesterase inhibition.
6. A 67-year-old woman with Parkinson's disease has been taking selegiline 5 mg twice daily for motor symptom control for three years. She develops significant depression and her primary care physician, unfamiliar with her neurological regimen, prescribes paroxetine 20 mg daily. She takes both medications together for five days before her neurologist is notified. On day five she presents to the emergency department with agitation, diaphoresis, tremor, hyperreflexia, and a temperature of 38.8°C. Which of the following correctly identifies the interaction, explains the mechanism producing these findings, and identifies the most important immediate management step?
A) The patient is experiencing a dopaminergic crisis from selegiline-mediated potentiation of paroxetine's indirect dopamine agonist effects; the findings reflect excessive dopaminergic stimulation of the motor cortex, and the treatment is immediate levodopa dose reduction plus benzodiazepine sedation
B) The patient is experiencing neuroleptic malignant syndrome triggered by paroxetine's D2 receptor partial agonism in the context of existing selegiline-mediated dopaminergic sensitization; immediate dantrolene and bromocriptine are the appropriate treatments
C) The patient is experiencing serotonin syndrome from the combination of selegiline — a MAO-B inhibitor that at standard doses reduces serotonin metabolism to some degree — and paroxetine, a potent serotonin reuptake inhibitor; the combination of reduced serotonin breakdown and blocked serotonin reuptake has caused synaptic serotonin accumulation producing the characteristic triad of autonomic instability, neuromuscular findings, and altered mental status; immediate discontinuation of both agents and supportive care are required
D) The patient is experiencing a hypertensive crisis from the tyramine-potentiating effect of selegiline combined with paroxetine's inhibition of hepatic MAO-A, which metabolizes dietary tyramine; the immediate treatment is intravenous phentolamine to block peripheral alpha-1 receptors
E) The patient is experiencing a cholinergic toxidrome from paroxetine's muscarinic receptor agonism combined with selegiline's inhibition of acetylcholinesterase in central cholinergic synapses; the immediate treatment is atropine to block peripheral muscarinic receptors
ANSWER: C
Rationale:
This vignette presents the clinical syndrome of serotonin syndrome — characterized by the diagnostic triad of autonomic instability (diaphoresis, hyperthermia), neuromuscular abnormalities (tremor, hyperreflexia), and altered mental status (agitation) — arising from the pharmacodynamic interaction between selegiline and paroxetine. Selegiline is a selective MAO-B inhibitor at standard doses, acting predominantly on the isoform that metabolizes dopamine rather than serotonin; in general, MAO-B inhibitor plus serotonergic combinations are well tolerated and serotonin syndrome is rare. Paroxetine, however, is a potent inhibitor of the serotonin reuptake transporter (SERT) — among the SSRIs with the most potent SERT inhibition — and is specifically listed in prescribing information as contraindicated with MAO-B inhibitors; it also inhibits CYP2D6, which contributes to selegiline metabolism, adding a pharmacokinetic dimension to the interaction. The combination of reduced serotonin breakdown (selegiline) and blocked serotonin reuptake (paroxetine) produces synaptic serotonin accumulation that activates 5-HT1A and 5-HT2A receptors to produce the syndrome. Immediate management requires discontinuing both agents and providing supportive care; in severe cases, cyproheptadine (a 5-HT2A antagonist) may be used, and benzodiazepines address the neuromuscular hyperactivity.
Option A: Option A is incorrect because the findings — diaphoresis, hyperreflexia, hyperthermia, agitation — are not consistent with a dopaminergic crisis, which typically presents with motor worsening rather than hyperreflexia and autonomic activation; and paroxetine has no meaningful indirect dopamine agonist activity.
Option B: Option B is incorrect because neuroleptic malignant syndrome is caused by dopamine receptor blockade (typically from antipsychotics or withdrawal of dopaminergic agents) and presents with rigidity, bradykinesia, and elevated creatine kinase; paroxetine does not block D2 receptors and this syndrome does not match NMS criteria.
Option D: Option D is incorrect because selegiline-mediated tyramine potentiation is a concern when MAO-A is substantially inhibited, but selective MAO-B inhibitors at therapeutic doses do not significantly inhibit MAO-A in the gut and liver; moreover, paroxetine does not inhibit MAO-A.
Option E: Option E is incorrect because paroxetine does not agonize muscarinic receptors — it is a serotonin reuptake inhibitor — and selegiline does not inhibit acetylcholinesterase; the syndrome is serotonergic, not cholinergic.
7. A 71-year-old woman with Parkinson's disease has been receiving botulinum toxin type A injections into her right tibialis posterior and gastrocnemius muscles every three months for off-period foot dystonia with excellent initial results — near-complete relief lasting 10 to 12 weeks after each injection. After her fifth injection, she reports that the benefit lasted only six weeks. After her sixth injection, the benefit lasted only four weeks and seemed less complete. Repeat polysomnography and levodopa regimen review are unchanged. Which of the following most accurately explains this change in treatment response and identifies the appropriate next step?
A) The shortened duration reflects progressive degeneration of the neuromuscular junctions in the injected muscles as a direct toxic effect of repeated botulinum toxin exposure; the appropriate response is to discontinue botulinum toxin permanently and substitute oral baclofen for dystonia management
B) The shortened duration and reduced efficacy are consistent with the development of neutralizing antibodies against botulinum toxin type A, which bind and inactivate the toxin before it can act at the neuromuscular junction; switching to botulinum toxin type B (a distinct serotype with a different antigenic profile) is the appropriate next step to restore therapeutic effect
C) The shortened duration reflects tachyphylaxis at the neuromuscular junction — botulinum toxin type A downregulates the SNAP-25 protein it cleaves, reducing the number of available cleavage sites with repeated injections; increasing the total dose injected per session by 50% will overcome this receptor-level adaptation
D) The shortened duration is caused by progressive atrophy of the injected muscles from repeated denervation, which reduces the muscle mass available to respond to botulinum toxin; the appropriate response is to add physiotherapy to maintain muscle bulk and inject at higher concentrations to reach the atrophied fibers
E) The shortened duration reflects a pharmacokinetic change — repeated injections have induced local fibrosis that reduces botulinum toxin diffusion from the injection site, limiting the volume of neuromuscular junctions exposed to the drug; switching to a higher-volume injection technique using the same serotype will restore the original duration of effect
ANSWER: B
Rationale:
This vignette presents the characteristic clinical pattern of secondary non-response to botulinum toxin — gradual shortening and reduction of therapeutic effect after an initial period of good response — which is the established clinical presentation of neutralizing antibody formation. Botulinum toxin type A is a bacterial protein; with repeated injections, some patients develop immunoglobulin G antibodies that bind to the toxin and prevent it from cleaving its presynaptic SNAP-25 target, reducing or eliminating the neuromuscular blockade. The risk of antibody formation is related to the total protein dose per injection, the frequency of injections, and individual immunological factors. When secondary non-response is identified, switching to botulinum toxin type B — a serotype with a different heavy chain structure and antigenic epitopes — can restore therapeutic effect because type A-neutralizing antibodies do not cross-react with type B.
Option A: Option A is incorrect because botulinum toxin does not cause progressive neuromuscular junction degeneration with repeated use; its effect is reversible and the junction fully recovers as new SNAP-25 protein is synthesized and axonal sprouting restores acetylcholine release; the toxin does not permanently damage the junction.
Option C: Option C is incorrect because SNAP-25 downregulation causing reduced cleavage sites is not an established mechanism of tachyphylaxis to botulinum toxin; the pharmacological mechanism of secondary non-response is antibody-mediated neutralization rather than receptor-level adaptation, and increasing the dose of a type A preparation that is being neutralized by antibodies will not overcome antibody-mediated inactivation.
Option D: Option D is incorrect because while some degree of muscle atrophy does occur with repeated botulinum toxin injections, this is a minor and generally manageable effect that does not explain the pattern of progressively shortening duration observed here; antibody-mediated secondary non-response is the clinically established explanation for this time course.
Option E: Option E is incorrect because local fibrosis affecting diffusion is not the established explanation for secondary non-response following repeated injections; pharmacokinetic diffusion issues would not produce the pattern of gradually shortening duration seen over multiple injection cycles with a previously effective dose.
8. A 74-year-old man with a 10-year history of Parkinson's disease undergoes elective laparoscopic cholecystectomy. Postoperatively he develops nausea and vomiting. The anesthesiologist, who is not aware of the interaction risks in Parkinson's disease, orders prochlorperazine 10 mg IV — a standard antiemetic choice for postoperative nausea and vomiting. The circulating nurse pages the ward pharmacist before administering the drug. Which of the following correctly identifies the pharmacological basis for the pharmacist's concern and specifies the most appropriate safe antiemetic substitution?
A) Prochlorperazine is contraindicated in Parkinson's disease because it is a potent inhibitor of aromatic L-amino acid decarboxylase, reducing the conversion of levodopa to dopamine in peripheral tissues and causing a functional levodopa deficiency that worsens motor symptoms; ondansetron does not inhibit AADC and is therefore safe
B) Prochlorperazine is contraindicated because it blocks the hepatic CYP1A2 enzyme responsible for metabolizing levodopa, causing toxic levodopa accumulation; metoclopramide is the preferred safe substitution because it does not affect CYP1A2
C) Prochlorperazine is contraindicated because it activates peripheral dopamine D1 receptors in the gut, producing a paradoxical increase in gastrointestinal dopaminergic tone that interferes with the therapeutic effect of levodopa at enteric dopamine receptors; domperidone is the safe alternative because it selectively blocks enteric D1 receptors
D) Prochlorperazine is a phenothiazine antipsychotic that blocks central dopamine D2 receptors; in a patient with Parkinson's disease whose motor symptoms are controlled by dopaminergic therapy, central D2 blockade will directly antagonize treatment and cause severe acute motor worsening; ondansetron, a serotonin 5-HT3 antagonist with no dopamine receptor activity, is the appropriate safe substitution
E) Prochlorperazine is contraindicated because it is a selective MAO-A inhibitor that will interact with any levodopa in the patient's system to produce a hypertensive crisis through tyramine-like indirect sympathomimetic activity; ondansetron is safe because it does not affect monoamine oxidase
ANSWER: D
Rationale:
This vignette presents the inpatient antiemetic prescribing error that is one of the most common and dangerous pharmacological pitfalls in Parkinson's disease management. Prochlorperazine is a phenothiazine antipsychotic with potent dopamine D2 receptor antagonist activity — the same receptor blockade mechanism that makes all first-generation antipsychotics contraindicated in PD. By blocking central D2 receptors in the basal ganglia, prochlorperazine directly antagonizes the dopaminergic motor therapy that is controlling this patient's symptoms, causing acute and potentially severe worsening of rigidity, bradykinesia, and postural instability. Even a single intravenous dose carries meaningful risk. Ondansetron is a serotonin 5-HT3 receptor antagonist that exerts its antiemetic effect by blocking serotonergic signaling in the chemoreceptor trigger zone and vagal afferents — it has no dopamine receptor activity and is safe in PD. Domperidone is an alternative D2 antagonist antiemetic that is also acceptable because it does not cross the blood-brain barrier at standard doses.
Option A: Option A is incorrect because prochlorperazine does not inhibit aromatic L-amino acid decarboxylase; AADC inhibition is not its mechanism of action or contraindication in PD — central D2 receptor blockade is the relevant mechanism.
Option B: Option B is incorrect because prochlorperazine does not inhibit CYP1A2, and levodopa is not metabolized by CYP1A2; this pharmacokinetic mechanism is fabricated; and metoclopramide is also a D2 blocker and is itself contraindicated in PD — it is not a safe substitute.
Option C: Option C is incorrect because prochlorperazine does not activate D1 receptors; it is a D2 antagonist, not a D1 agonist; and domperidone is a D2 antagonist that does not block D1 receptors.
Option E: Option E is incorrect because prochlorperazine is not a MAO-A inhibitor; monoamine oxidase inhibition is not part of phenothiazine pharmacology, and a hypertensive crisis from tyramine-like activity is not the mechanism of the contraindication.
9. A 72-year-old woman with Parkinson's disease and mild cognitive impairment is seen by her urologist for urinary urgency and frequency. The urologist prescribes solifenacin 5 mg daily. At her next neurology appointment six weeks later, her husband reports that she has become significantly more confused, has had two episodes of not recognizing her own home, and had one episode of visual hallucinations. Her MMSE has declined from 24 to 19 out of 30. Her antiparkinson regimen is unchanged. Which of the following best identifies the cause of her cognitive decline and specifies the correct pharmacological substitution?
A) Solifenacin, a muscarinic M3 receptor antagonist prescribed for overactive bladder, carries significant anticholinergic cognitive burden; in a patient with Parkinson's disease and pre-existing mild cognitive impairment — who already has a severe cholinergic deficit — muscarinic receptor blockade has precipitated a clinically significant cognitive decline; solifenacin should be discontinued and mirabegron, a beta-3 adrenergic agonist with no anticholinergic mechanism, substituted for bladder symptom control
B) The cognitive decline is caused by solifenacin's inhibition of dopamine reuptake in the prefrontal cortex, which paradoxically reduces frontal lobe arousal in a dopamine-deficient PD patient; the appropriate substitution is oxybutynin extended-release, which has a more selective peripheral action and does not affect prefrontal dopamine
C) The cognitive decline is a natural progression of Parkinson's disease dementia unrelated to solifenacin, which at 5 mg daily does not achieve plasma concentrations sufficient to cross the blood-brain barrier in patients over 70; the urologist should continue solifenacin and the neurologist should initiate rivastigmine for the underlying dementia
D) The cognitive decline reflects solifenacin-induced inhibition of acetylcholinesterase in the prefrontal cortex, reducing acetylcholine hydrolysis and causing cholinergic excess that paradoxically impairs cognition through receptor desensitization; the appropriate treatment is to add a low-dose anticholinergic to rebalance the cholinergic system
E) The cognitive decline is caused by solifenacin's weak MAO-B inhibitory activity, which in combination with the patient's existing dopaminergic medications has produced a mild dopamine excess syndrome affecting prefrontal executive function; dose reduction of her dopamine agonist will correct the imbalance without requiring solifenacin discontinuation
ANSWER: A
Rationale:
This vignette illustrates the principle that anticholinergic bladder agents are contraindicated in Parkinson's disease patients with cognitive impairment and should be replaced by mirabegron. Solifenacin is a selective muscarinic M3 receptor antagonist used for overactive bladder. Despite being labeled as peripherally selective, solifenacin crosses the blood-brain barrier to a meaningful degree and exerts central anticholinergic effects — particularly at the doses used clinically. In a patient with Parkinson's disease dementia or pre-existing mild cognitive impairment, the baseline cholinergic deficit is already severe; adding muscarinic receptor blockade at central cholinergic synapses directly worsens the neurotransmitter deficit responsible for both cognitive and neuropsychiatric symptoms. The five-point MMSE decline, new confusion, disorientation, and visual hallucinations over six weeks of solifenacin use in an otherwise stable patient constitute strong evidence of drug-induced anticholinergic cognitive toxicity. Mirabegron relaxes the detrusor through beta-3 adrenergic receptor activation — a mechanism with no anticholinergic component — and is the pharmacologically appropriate substitution.
Option B: Option B is incorrect because solifenacin does not inhibit dopamine reuptake; it is a selective muscarinic antagonist with no dopaminergic mechanism; and oxybutynin extended-release carries substantial anticholinergic CNS burden and is a worse choice than solifenacin, not a safer one.
Option C: Option C is incorrect because solifenacin does cross the blood-brain barrier at clinical doses and does cause central anticholinergic effects — claiming it cannot cross the BBB in patients over 70 is pharmacologically inaccurate; and attributing the decline to natural disease progression in the context of a clear temporal relationship to drug initiation dismisses a correctable cause.
Option D: Option D is incorrect because solifenacin is a muscarinic receptor antagonist, not an acetylcholinesterase inhibitor; it does not inhibit acetylcholine hydrolysis or cause cholinergic excess — the description inverts solifenacin's mechanism entirely.
Option E: Option E is incorrect because solifenacin has no MAO-B inhibitory activity; this mechanism is pharmacologically fabricated and does not explain any aspect of solifenacin's adverse effect profile.
10. A 64-year-old man with Parkinson's disease and excessive daytime sleepiness (EDS) has been switched from pramipexole to rotigotine transdermal patch two months ago in an attempt to reduce sedation, as pramipexole was identified as the most likely contributor to his EDS. At today's visit he reports that his sleepiness has improved somewhat but he is still falling asleep during the day without warning. He also discloses that last week he nearly drove off the road when he fell asleep at the wheel for several seconds. He drives to work daily. Which of the following represents the most complete and pharmacologically appropriate management response?
A) Switch from rotigotine back to pramipexole at a lower dose; the near-miss driving episode indicates that rotigotine's transdermal delivery is producing unpredictable plasma concentration spikes that cause sudden sleep episodes, whereas pramipexole's oral pharmacokinetics produce more predictable sedation that the patient can anticipate and manage
B) Add caffeine 200 mg twice daily as a first-line wake-promoting agent; caffeine's adenosine A2A receptor antagonism is particularly effective in PD because adenosine A2A receptors are highly expressed in the basal ganglia, and caffeine's wakefulness-promoting effects are superior to modafinil in this receptor context
C) Reassure the patient that EDS always improves with time after dopamine agonist switching and that no additional pharmacological intervention is needed; instruct him to avoid driving only during the first hour after taking his morning medications when plasma concentrations are highest
D) Add sodium oxybate at bedtime to consolidate nocturnal sleep and reduce EDS; sodium oxybate has the strongest evidence base for reducing excessive daytime sleepiness in PD and is the preferred agent when dopamine agonist switching has not fully resolved EDS
E) Instruct the patient to stop driving immediately until his EDS is adequately controlled, as the near-miss episode represents an active safety risk to himself and others; add modafinil 100 mg in the morning as a wake-promoting agent with evidence for EDS in PD, and arrange a follow-up within two to four weeks to reassess driving fitness before any return to driving
ANSWER: E
Rationale:
This vignette requires integrating the pharmacological management of EDS in PD with the patient safety and driving fitness obligations that arise from a documented sudden sleep episode while driving. A near-miss driving incident from uncontrolled EDS is a patient safety emergency that supersedes all other management considerations — the patient must be instructed to stop driving immediately. This is not merely a recommendation; unexplained loss of consciousness or control while driving creates legal and ethical obligations for the treating physician in most jurisdictions, and the physician must clearly communicate both the safety risk and the requirement to cease driving until EDS is adequately controlled. Pharmacologically, modafinil 100 mg each morning is the appropriate addition — it has randomized controlled trial evidence for improving subjective EDS in PD and is the most widely used wake-promoting agent for this indication. Rotigotine, while generally less sedating than pramipexole, has not fully resolved the EDS, confirming that the EDS has both dopaminergic and disease-intrinsic components. Follow-up within two to four weeks allows reassessment of driving fitness before any return to driving.
Option A: Option A is incorrect because switching back to pramipexole — the more sedating agent — after the patient has already had a dangerous driving episode is not appropriate; the clinical priority is reducing EDS, not returning to the prior agent, and plasma concentration spikes from rotigotine causing sudden sleep episodes is not an established pharmacokinetic phenomenon.
Option B: Option B is incorrect because while caffeine has adenosine A2A receptor antagonism and some evidence for modest wakefulness promotion in PD, it is not established as superior to modafinil for EDS management and is not the standard pharmacological choice for this indication; more importantly, this option fails to address the driving safety emergency.
Option C: Option C is incorrect because reassuring the patient and providing a partial driving restriction (only the first hour) after a documented near-miss episode is clinically and ethically inadequate — a near-miss from sudden sleep at the wheel requires complete cessation of driving until the EDS is controlled, not a partial time-of-day restriction.
Option D: Option D is incorrect because sodium oxybate, while studied for EDS in PD with some evidence for nocturnal sleep consolidation and daytime function, is not the first-line pharmacological choice after dopamine agonist switching — modafinil is; and sodium oxybate's Schedule III classification and complex REMS distribution requirements make it substantially less accessible as a first-line add-on than modafinil.
11. A 68-year-old man with Parkinson's disease has been treated with gabapentin 600 mg at bedtime for restless legs syndrome (RLS) for eight months. He now reports that his RLS symptoms have become worse — they start earlier in the day, have spread to his arms, and are more intense than before he started gabapentin. His neurologist considers a diagnosis of augmentation and plans to switch to a different agent. Before changing therapy, which of the following represents the most pharmacologically accurate assessment of this clinical situation?
A) The clinical picture is consistent with augmentation from gabapentin; gabapentin causes augmentation through its alpha-2-delta calcium channel ligand mechanism, which upregulates voltage-gated calcium channels in RLS-relevant spinal circuits over time, producing a rebound hypersensitivity that worsens RLS; switching to a dopamine agonist is the appropriate next step
B) The worsening RLS symptoms represent tolerance to gabapentin's alpha-2-delta binding — the drug has downregulated its own receptor targets over eight months, and doubling the dose to 1200 mg will overcome the tolerance and restore the original therapeutic effect without requiring a drug change
C) Augmentation is a complication specific to dopamine agonist therapy for RLS and does not occur with alpha-2-delta ligands such as gabapentin; the worsening symptoms in this patient require a reassessment of the diagnosis — possible explanations include inadequate gabapentin dosing, a superimposed cause of RLS worsening such as iron deficiency or uremia, or an alternative diagnosis; the next step is clinical reassessment and investigation rather than an automatic agent switch
D) The worsening RLS symptoms confirm that gabapentin is contraindicated in patients with Parkinson's disease because its alpha-2-delta mechanism inhibits the nigrostriatal dopaminergic terminals that control RLS symptoms in PD patients, producing a paradoxical worsening; switching to pramipexole, which directly stimulates D2/D3 receptors, is the mechanistically correct intervention
E) The clinical picture is consistent with augmentation, confirming that all pharmacological agents used for RLS — including dopamine agonists, alpha-2-delta ligands, opioids, and iron supplementation — share a common augmentation mechanism through progressive sensitization of spinal cord nociceptive pathways; opioids should be tried next as they are the only class that does not cause augmentation through this pathway
ANSWER: C
Rationale:
This vignette tests a precise pharmacological distinction that is clinically important: augmentation is a complication specific to dopamine agonist therapy for RLS and has not been demonstrated to occur with alpha-2-delta calcium channel ligands such as gabapentin or pregabalin. Indeed, one of the primary reasons alpha-2-delta ligands are increasingly preferred over dopamine agonists for RLS is precisely their freedom from augmentation risk. A patient on gabapentin who develops worsening RLS that resembles the augmentation pattern (earlier onset, spread, increased intensity) cannot have drug-induced augmentation from gabapentin — and incorrectly labeling this as augmentation risks switching the patient from a non-augmenting agent to a dopamine agonist, which does cause augmentation. The correct response is clinical reassessment: evaluate whether the gabapentin dose is adequate (600 mg may be insufficient for some patients), investigate for secondary causes of RLS worsening (iron deficiency anemia, renal failure, pregnancy, new medications), and consider whether the original diagnosis is correct.
Option A: Option A is incorrect because gabapentin does not cause augmentation — this is the pharmacologically central error the question is designed to test; alpha-2-delta ligands act on the auxiliary subunit of voltage-gated calcium channels and do not produce the paradoxical receptor sensitization that characterizes dopamine agonist-induced augmentation.
Option B: Option B is incorrect because while tolerance to gabapentin's sedative effects can develop, a pharmacodynamically driven tolerance causing progressively worsening RLS is not the established explanation for this pattern; the clinical picture requires reassessment rather than automatic dose escalation without investigation.
Option D: Option D is incorrect because gabapentin is not contraindicated in PD and does not inhibit nigrostriatal dopaminergic terminals; alpha-2-delta ligands do not act on dopamine terminals and are a recommended treatment option for RLS in PD patients.
Option E: Option E is incorrect because augmentation is not a mechanism shared by all RLS treatment classes — it is specifically associated with dopamine agonists and does not occur with alpha-2-delta ligands, opioids, or iron supplementation; characterizing augmentation as a universal RLS drug complication is pharmacologically inaccurate.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.